IMAC Regeneration Centers Annual Analysis Shows 81% of Patients Report Improvement in Functional Outcomes from Treatment of M...
May 27 2021 - 9:00AM
IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative
medical advancements and care specializing in regenerative
rehabilitation orthopedic treatments without the use of surgery or
opioids, today announced results from an extensive internal
analysis of treatment outcomes for musculoskeletal conditions
performed at IMAC Regeneration Centers, which showed approximately
81% of IMAC patients reported improvement in movement, which is
consistent with the data measured over the past three years.
IMAC analyzed functional disabilities primarily
affecting the knees, lower back, neck, shoulders, hips, legs and
ankles. Data was collected from patients during initial
examinations, re-examinations and at discharge intervals during
patients’ course of care. IMAC examined patient functional
improvement following treatment at IMAC Regeneration Centers
between 2017 and the first quarter of 2021 utilizing standardized
disability indexes.
A total of 875 patients with an average age of
72 years and receiving 80.7 days of treatment were evaluated with
each patient receiving non-opioid medical treatments in combination
with physical therapy. More than 81%, or 712, exhibited up to 79%
improvement in functionality. For the study, 152 patients showed
less than 1% change in functional ability, and only 11 patients
regressed.
“This clinical data demonstrates that our
non-opioid, non-surgical regenerative rehabilitation therapies
improve recovery from movement restrictions and physical injuries.
Our affordable services prove to be an effective, conservative care
alternative for most people facing a joint replacement or spinal
fusion surgery,” stated Jeff Ervin, Chief Executive Officer of
IMAC. “Three consecutive years of measurable performance outcomes
gives our medical team confidence when addressing degenerative
orthopedic conditions for our patients.”
In IMAC’s analysis, the percentage of patients
reporting improvement for each disability category was as follows:
81% of those treated for knee conditions, 80% of those treated for
lower back conditions, 90% of those treated for neck conditions,
73% of those treated for shoulder conditions, 78% treated for hip
conditions, 86% treated for leg conditions and 80% of those with
ankle conditions. The average treatment duration was 80.87 days,
and the average patient age was 72.2 years.
About IMAC Holdings, Inc.
IMAC was created in March 2015 to expand on the
footprint of the original IMAC Regeneration Center, which opened in
Kentucky in August 2000. IMAC Regeneration Centers combine
life-science advancements with traditional medical care for
movement restricting diseases and conditions. IMAC owns or manages
more than 15 outpatient clinics that provide regenerative,
orthopedic and minimally invasive procedures and therapies. It has
partnered with several active and former professional athletes
including Ozzie Smith, David Price, Mike Ditka and Tony Delk.
IMAC’s outpatient medical clinics emphasize treating sports and
orthopedic injuries and movement-restricting diseases without
surgery or opioids. More information about IMAC Holdings, Inc. is
available at www.imacholdings.com.
# # #
Safe Harbor Statement
This press release contains forward-looking
statements. These forward-looking statements, and terms such as
“anticipate,” “expect,” “believe,” “may,” “will,” “should” or other
comparable terms, are based largely on IMAC's expectations and are
subject to a number of risks and uncertainties, certain of which
are beyond IMAC's control. Actual results could differ materially
from these forward-looking statements as a result of, among other
factors, risks and uncertainties associated with its ability to
raise additional funding, its ability to maintain and grow its
business, variability of operating results, its ability to maintain
and enhance its brand, its development and introduction of new
products and services, the successful integration of acquired
companies, technologies and assets, marketing and other business
development initiatives, competition in the industry, general
government regulation, economic conditions, dependence on key
personnel, the ability to attract, hire and retain personnel who
possess the skills and experience necessary to meet customers’
requirements, and its ability to protect its intellectual property.
IMAC encourages you to review other factors that may affect its
future results in its registration statement and in its other
filings with the Securities and Exchange Commission. In light of
these risks and uncertainties, there can be no assurance that the
forward-looking information contained in this press release will in
fact occur.
IMAC Press Contact: Laura Fristoelfristoe@imacrc.com
Investors Bret Shapiro(516) 222-2560brets@coreir.com
Source: IMAC Holdings, Inc.
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Apr 2023 to Apr 2024